全身麻醉与神经生理引导下丘脑底核脑深部电刺激术并持续多巴胺能药物治疗:比较队列研究
研究组30例帕金森病患者在全身麻醉与微电极记录引导下行丘脑底核脑深部电刺激术并持续多巴胺能药物治疗,与术前停药的历史对照组比较。两组术中神经生理参数相当,研究组总恢复时间有缩短趋势但未达统计学显著,运动评分改善与左旋多巴每日等效剂量减少相当;研究组无多巴胺撤药副作用,对照组发生率为15%。
要点
- 持续多巴胺能药物治疗不影响丘脑底核脑深部电刺激术的可行性与结局。
- 研究组无多巴胺撤药副作用,历史对照组发生率为15%。
- 研究组总恢复时间60分钟 vs 对照组89分钟,p=0.09,差异未达统计学显著。
核心结论
- 持续多巴胺能药物治疗不影响帕金森病患者丘脑底核脑深部电刺激术的可行性与结局。
- 该策略似乎可降低多巴胺撤药不良反应风险,并可能改善术后即刻恢复,有助于提升患者围手术期体验。
研究设计与样本
- 前瞻性队列分析,研究组n=30(2014年5月至2016年1月),为持续多巴胺能药物治疗至全身麻醉给药的患者。
- 对照组为术前停用多巴胺能药物治疗的历史对照队列。
- 比较基线特征、术中神经生理标志物、围手术期并发症、长期运动评分及术后恢复指标。
主要发现
- 研究组年龄60(51-64)岁 vs 对照组64(56-69)岁,p=0.043。
- 微电极记录轨迹数:研究组60%为单轨迹 vs 对照组58%,p=1.0。
- 检测到的丘脑底核微电极记录长度:研究组9 mm vs 对照组7 mm(中位数),p=0.037。
- 总恢复时间:研究组60(50-84)分钟 vs 对照组89(62-120)分钟,p=0.09,差异未达统计学显著。
- 长期运动评分改善与左旋多巴每日等效剂量减少两组相当;研究组无多巴胺撤药或术后即刻运动障碍问题,对照组多巴胺撤药副作用发生率为15%。
临床怎么用
- 作者认为,帕金森病患者行丘脑底核脑深部电刺激术时可继续多巴胺能药物治疗,该策略似乎可降低多巴胺撤药不良反应风险并可能改善术后即刻恢复。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The authors have previously reported on the technical feasibility of subthalamic nucleus deep brain stimulation (STN DBS) under general anesthesia (GA) with microelectrode recording (MER) guidance in Parkinsonian patients who continued dopaminergic therapy until surgery. This paper presents the results of a prospective cohort analysis to verify the outcome of the initial study, and report on wider aspects of clinical outcome and postoperative recovery. METHODS: All patients in the study group continued dopaminergic therapy until GA was administered. Baseline characteristics, intraoperative neurophysiological markers, and perioperative complications were recorded. Long-term outcome was assessed using selective aspects of the unified Parkinson's disease rating scale motor score. Immediate postoperative recovery from GA was assessed using the "time needed for extubation" and "total time of recovery." Data for the "study group" was collected prospectively. Examined variables were compared between the "study group" and "historical control group" who stopped dopaminergic therapy preoperatively. RESULTS: The study group, n = 30 (May 2014-Jan 2016), were slightly younger than the "control group," 60 (51-64) vs. 64 (56-69) years respectively, p = 0.043. Both groups were comparable for the recorded intraoperative neurophysiological parameters; "number of MER tracks": 60% of the "study group" had single track vs. 58% in the "control" group, p = 1.0. Length of STN MER detected was 9 vs. 7 mm (median) respectively, p = 0.037. A trend towards better recovery from GA in the study group was noted, with shorter "total recovery time": 60 (50-84) vs. 89 (62-120) min, p = 0.09. Long-term improvement in motor scores and reduction in L-dopa daily equivalent dose were equally comparable between both groups. No cases of dopamine withdrawal or problems with immediate postop dyskinesia were recorded in the "on medications group." The observed rate of dopamine-withdrawal side effects in the "off-medications" group was 15%. CONCLUSIONS: The continuation of dopaminergic treatment for patients with PD does not affect the feasibility/outcome of the STN DBS surgery. This strategy appears to reduce the risk of dopamine-withdrawal adverse effects and may improve the recovery in the immediate postoperative period, which would help enhance patients' perioperative experience.
引用
- Asha MJ, Fisher B, Kausar J, et al. Subthalamic deep brain stimulation under general anesthesia and neurophysiological guidance while on dopaminergic medication: comparative cohort study. Acta Neurochir (Wien). 2018. PMID: 29396602. doi:10.1007/s00701-018-3473-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。